Emerging approaches to treat immune disorders target positive regulatory kinases downstream of antigen receptors with small molecule inhibitors. Here we provide evidence for an alternative approach in which inhibition of the negative regulatory inositol kinase Itpkb in mature T lymphocytes results in enhanced intracellular calcium levels following antigen receptor activation leading to T cell death. Using Itpkb conditional knockout mice and LMW Itpkb inhibitors these studies reveal that Itpkb through its product IP4 inhibits the Orai1/ Stim1 calcium channel on lymphocytes. Pharmacological inhibition or genetic deletion of Itpkb results in elevated intracellular Ca 2+ and induction of FasL and Bim resulting in T cell apoptosis. Deletion of Itpkb or treatment with Itpkb inhibitors blocks T-cell dependent antibody responses in vivo and prevents T cell driven arthritis in rats. These data identify Itpkb as an essential mediator of T cell activation and suggest Itpkb inhibition as a novel approach to treat autoimmune disease.
Introduction
Lymphocytes become pathogenic when tolerance to self-tissues is lost, often resulting in the onset of autoimmune disease. Receptors that trigger immune cell activation are linked to phosphorylation events mediated by kinases, which has led to the idea that blocking kinases involved in cell activation with low molecular weight inhibitors (LMW) may be an effective way to treat autoimmune disease. Several kinase inhibitors are currently in clinical trials for numerous autoimmune indications, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis [1] . Current therapies such as Neoral (cyclosporin) and Prograf (FK506) target T lymphocytes by blocking the Ca 2+ -activated phosphatase, calcineurin, which mediates the dephosphorylation of NF-AT, a key transcription factor which drives effector gene expression and other canonical features of lymphocyte function [2] . In mature lymphocytes, the spatiotemporal regulation of Ca 2+ modulates signaling pathways that serve to control a variety of cellular responses, such as activation, differentiation, effector function, and cell death [3, 4] . Thus, targeting kinases involved in Ca 2+ responses is an attractive approach to treat immune disorders.
The activation of T lymphocytes through the T cell antigen receptor (TCR) results in PLCγ-mediated hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP 2 ) into IP 3 and diacylglycerol. IP 3 induces the release of Ca 2+ from endoplasmic reticulum (ER) stores and the subsequent influx of Ca 2+ into the cytosol through store-operated Ca 2+ (SOC) channels in the plasma membrane following store depletion. Two key components of the SOC channel pathway in lymphocytes, often referred to as calcium-release activated calcium (CRAC) channels, were identified as stromal interaction molecule 1 (Stim1) and Orai1. Stim1 senses Ca 2+ depletion in the ER via its EF hand and subsequently translocates to the plasma membrane where it interacts with Orai1, a pore subunit of the CRAC channels that ultimately permits a sustained increase in cytosolic Ca 2+ [3] [4] [5] [6] [7] . While much of the signaling machinery leading to the induction of Ca 2+ entry in lymphocytes have been identified, the components and mechanisms by which Ca 2+ is negatively regulated are incompletely understood.
The soluble second messenger, IP 3 , can be further phosphorylated by inositol kinases into higher order inositol phosphates [8] . The Ca 2+ -dependent kinase, inositol trisphosphate 3' kinase B (Itpkb), phosphorylates the 3' position of Ins (1, 4, 5) P3 to generate inositol 1,3,4,5-tetrakisphosphate [Ins (1, 3, 4, 5) P4] [9] . The importance of Itpkb, and consequently Ins(1,3,4,5)P4, in the immune system is exemplified by Itpkb-deficient mice which lack peripheral T cells due to a block at the CD4 + CD8 + stage of thymocyte development [10, 11] . In addition, B cell development is significantly impaired [12, 13] . Itpkb-deficient thymocytes and B cells exhibit enhanced SOC channel activity following antigen receptor stimulation, which is reversed upon treatment with exogenous Ins(1,3,4,5)P4. Furthermore, upon thapsigargin treatment, a condition that artificially opens SOC channels independent of other inositol phosphates, Ins (1, 3, 4, 5) P4 is able to inhibit channel activity [13] . These data indicate that Itpkb, and its product Ins (1, 3, 4, 5) P4, are crucial negative regulators of SOC channels in lymphocytes, however, the precise mechanism is unknown [12, 13] . Due to the block in thymocyte development and defects in B cell development, the role of Itpkb in mature lymphocytes is also not known.
To elucidate the role of Itpkb in mature lymphocytes, we generated an inducible Itpkb knock-out mouse line using the tamoxifen-induced ERT2-Cre/LoxP system. Here we show that in addition to playing a critical role in lymphocyte development, Itpkb is required for mature T cell survival. In vivo, conditional Itpkb-knockout mice fail to generate antibody responses to a T-dependent antigen, while T-independent antibody responses remain intact. Itpkb-deficient T cells fail to proliferate following TCR stimulation; and TCR-mediated SOC responses are enhanced. Electrophysiological analysis revealed that the product of Itpkb, Ins (1,3,4,5)P4 rapidly inhibits Orai1-mediated current in intact cells. TCR stimulation of Itpkbdeficient T cells leads to enhanced expression of genes involved in apoptosis, such as Bim and FasL, and blocking the Fas-FasL interaction partially rescued the observed proliferative defect. To explore the therapeutic potential of targeting Itpkb for T cell-mediated autoimmune diseases, a selective, potent, and orally bioavailable LMW inhibitor of Itpkb, GNF362, was identified via high-throughput compound screening and optimized for drug-like properties using medicinal chemistry. Application of GNF362 to lymphocytes in vitro, blocked Ins (1, 3, 4, 5) 
Materials and Methods Mice
All animal work was approved by the Genomics Institute of the Novartis Research Foundation (GNF) Institutional Animal Care and Use Committee (IACUC) committee. All mice were maintained in a specific pathogen-free facility at the GNF. Itpkb-deficient mice (MsTless) on a C57BL/6 background were generated as previously described [11] . Conditional Itpkb-deficient mice (Itpkb fl/fl ) were generated by constructing a targeting vector containing exon 2 of Itpkb flanked with two loxP sites (S1 Fig). A neomycin-resistant gene cassette located within the two loxP sites was flanked by FRT sites. Following confirmation of gene targeting in CJ7 ES cells we generated chimeric mice by injecting targeted ES cells into C57BL/6-Tyr(c-2J) blastocysts and implanting the embryos into pseudopregnant CD1 (ICR) mice. Male chimeric mice were bred with the FLPeR female mice to delete the neomycin cassette in vivo. The Itpkb floxed mice (Itpkb fl/fl ) were then bred with the ROSA26 Cre−ERT2/+ transgenic mice, which express Cre recombinase fused to a mutated estrogen receptor ligand-binding domain, to ultimately generate Itpkb fl/fl ERT2-Cre transgenic mice whereby Itpkb can be inducibly deleted following treatment with Tamoxifen. Itpkb was inducibly deleted upon treatment with tamoxifen for 5 days, followed by 7 days of rest prior to experimental use. Since ER-Cre is expressed in all tissues, the efficiency of Itpkb could be assessed by PCR of genomic tail DNA. At the genomic level, the efficiency of deletion was estimated to be approximately 90%. These results indicate that Tamoxifen-induced Cre expression induced efficient deletion of Itpkb in all cells. This method of Itpkb deletion was used in all experiments presented here. All of the mice used for experiments presented in this paper were between 6 to 14 weeks of age and between 1 and 4 generations backcrossed to the C57BL/6 background. Mice which were backcrossed at least 4 generations exhibited 95% C57BL/6 genome contribution.
5-10 min on ice, then surface stained with either CD3-PB (BD), CD8-FITC (BD), B220-PE (BD), IgM-APC (BD) and CD4-APC-Cy7 (BioLegend) for splenocyte staining or CD3-PB (BD), CD69-FITC (BD), TCR-beta (BD), CD4-APC (eBioscience) and CD8-APC-Cy7 (BioLegend) for thymocyte staining. Cells were stained for 30-60 minutes on ice, protected from light. Cells were washed twice and resuspended in either 150 μl FACS buffer to read immediately or BD stabilizer Fixative (BD) for later analysis on the BD LSR II flow cytometer.
Immunizations
Itpkb +/+ and Itpkb fl/fl mice were immunized intraperitoneal (i.p.) with either 100 μl DNP-KLH/ Alum (Calbiochem) at 1mg/ml to assess T cell-dependent antibody responses, or with 100 μl TNP-(27)-AECE-Ficoll (BioSearch Technologies) to assess T cell-independent responses. Blood was obtained from mice before injection and post-immunization on day 9 for DNP-KLH and day 11 for TNP-Ficoll. Serum was analyzed by enzyme-linked immunosorbent assay (ELISA). ELISA plates (NUNC) were coated overnight at 4°C with TNP-BSA (BioSearch Technologies) at 50 μg/ml bi-carbonate buffer. Plates were washed 3 times (0.05% Tween/PBS), blocked with 1% BSA/PBS for 2 h at 25°C, then serial dilutions of serum samples were added, followed by incubation for 2 h at 25°C. Plates were washed six times before adding antiIgG1-HRP (US Biological, 1/2,000) or anti-IgG3-HRP (Jackson Lab, 1/5000) for 1 h at room temperature. Plates were washed six times, antibodies were detected with Super Aqua Blue substrate (eBioscience), stopped with 0.625 M Oxalic Acid (Fluka) and absorbance was measured at 405 nm.
Proliferation Assays
Spleens were removed from Itpkb +/+ and Itpkb fl/fl mice. Following RBC lysis, CD4 + T cells were purified by negative selection (Miltenyi Biotec) and resuspended in RPMI complete media containing 10% FCS, 2mM L-Glutamine, 100U penicillin, 100 μg/ml streptomycin, 10mM Hepes, 1x NEAA, 1mM Na Pyruvate and 50 μM 2-ME. 5x10 4 anti-CD3/28 beads, and incubated at 37°C. To evaluate FasL-mediated cell death, anti-FasL (MFL2) or American Hamster anti-IgG control antibody (eBioscience) at 5 μg/ml final concentration was added to the proliferation assay. After 72h, plates were harvested, washed with cold FACS buffer, and stained with Annexin V-Alexa Fluor647 (BioLegend) followed by 0.1 μg/ml of DAPI (Molecular Probes) and analysis on the flow cytometer.
Calcium Flux
Methods for analyzing intracellular calcium have been described previously [12, 13] 
Kinase Glo Assay
As described previously, Itpkb activity was determined by Kinase-Glo (Promega) [14] . Itpkb inhibitor dose response was carried out in 384well format with 60nM Itpkb, 2μM ATP, 200μM IP3, and 10% FBS at 25C for 1.5hr.
IP4 HPLC Assay
Jurkat cells were labeled with 3 H-MyoInositol in inositol free RPMI in the absence of serum for 6-8hrs at 37°C, then resuspended in RPMI with 10% FCS and incubated overnight. Cells were resuspended in the presence of compound prior to the addition of 1μg/mL of OKT3 and 1μg/ mL of anti-CD28 for 5 min at 37°C. After stimulation, cells were lysed in PBS with 3% HCL (0.36M final). 3 H inositols in cellular extracts were resolved by anion exchange HPLC and measured with an in-line β-ram detector.
Kinase selectivity panel GNF362 was tested in a panel of 159 protein and lipid kinases using Invitrogen Profiling Z'-lite kinase assay services. Briefly, GNF362 was tested in dose response in the presence of 10 μM ATP. Time-resolved fluorescence resonance energy transfer was utilized as the readout. Data shown represents the percent inhibition observed at 5μM.
FLIPR Ca 2+ Assay
Purified wild type splenocytes were labeled with the calcium-sensitive dye, Fluo4, plated onto fibronectin coated 384-well FLIPR plates, and spun at 1000rpm for 4min. Compound was transferred onto FLIPR plate at indicated concentrations, followed by stimulation with 30μg/ mL of Fab'2 anti-IgM in the presence of 1mM EGTA. Calcium readings were taken for 7.5min followed by the addition of 5mM Ca
2+
, and SOC-mediated Ca 2+ entry was measured for the final 5.5 minutes.
CD4 + T cell differentiation and intracellular staining
Purified CD4 + T cells from Itpkb +/+ and Itpkb fl/fl mice were stimulated at a 1:1 ratio with anti-CD3/28 beads in Th1-or Th2-skewing conditions. Th1 skewing conditions were anti-IL-4 (eBioscience, 5μg/ml), IL-12 (R&D Systems, 10ng/ml) and IL-2 (Peprotech, at 5ng/ml); Th-2 skewing conditions were IL-4 (R&D Systems, 5ng/ml), anti-IFNγ (eBioscience, 5μg/ml), anti-IL-12 (eBioscience, 4.25μg/ml) and IL-2 (5ng/ml); Cell were cultured at 37°C, for 6 days in the presence of exogenous IL-2 (5ng/ml). On day 6, 100K cells restimulated with anti-CD3/28 beads (~1:1 ratio) for 6 h at 37°C. The final 2h included Golgi stop (BD) and Golgi plug (BD). Cells were then surface stained with anti-CD4-APC-Cy7 (BioLegend), fixed, permeabilized, stained intracellularly with anti-IFNγ-APC, anti-IL4-PE (BioLegend), and anti-IL2-PE-Cy7 (eBioscience), and then run on the flow cytometer.
In vivo compound studies GNF362 was formulated at 2mg/mL in 20% hydroxyl propyl-beta cyclodextrin in water (vehicle). Wild type mice were then dosed orally with GNF362 at 3, 10, or 25mg/kg or vehicle twice daily for 9 days. The effect of GNF362 on thymocyte development was assessed by staining thymocytes for CD4-APC and CD8-APC-Cy7, as described above, and determining the percentage of CD4 + T cells by FACS analysis.
Rat AIA model
Lewis rats were immunized on Days − 21 and − 14 by subcutaneous injection of 100 μg methylated bovine serum albumin (mBSA) in 50 μl saline, emulsified in 50 μl complete Freund's adjuvant. GNF362 was then dosed orally at 6 or 20 mg/kg each day until the end of the study. On Day 0, 14d after the second immunization, the rats were given an intra-articular injection of mBSA (50μg) into the right knee joint. Knee joint swelling was monitored on Days 2, 4, and 7
by measuring knee diameters (mean of four readings), with the joint flexed at an angle of 90°, using a digital micrometer. At the termination of the study, paraffin sections were made and stained with Giemsa and Saffranin O, followed by histological analysis examining inflammatory cell infiltrate, joint damage, and proteoglycan loss scored on a 5-point scaling system. Lastly, serum antibody titers to mBSA were also measured on Day 7 serum.
Results

Itpkb is required for T cell development
To resolve the function of Itpkb in mature lymphocytes, we generated a mouse line whereby Itpkb could be deleted using the tamoxifen-induced ERT2-Cre/LoxP system (S1 and S2 Figs). [10, 11] . In contrast to the defects in thymocyte number, the percentage and number of B220 + and CD3 + cells in the spleen of Itpkb fl/fl are unchanged (Fig 1C and 1D) . These results contrast with dramatic loss of mature T cells observed in MsTless mice and suggests that Itpkb is not required for mature lymphocyte survival and homeostasis at this time point. Similar results were observed up to one month following tamoxifen treatment (data not shown).
Itpkb is required for T cell function by negatively regulating SOC channels
To address the role of Itpkb in mature T lymphocytes, we immunized Itpkb fl/fl and control Prior studies have implicated a role for Itpkb and its product, IP4, in controlling SOC channels in B cells and thymocytes [13] . To determine a role for Itpkb in regulating calcium levels in mature T lymphocytes we examined the calcium response following TCR cross-linking of CD4 + T cells from Itpkb fl/fl and Itpkb +/+ mice. Itpkb-deficient CD4 + T cells exhibit an increased calcium response compared to wild type cells (Fig 2D, top panel) . To determine whether the increased calcium response was due to enhanced SOC entry, CD4 + T cells were stimulated with anti-CD3 in the absence of exogenous calcium, followed by the re-addition of calcium. Itpkb-deficient CD4 + T cells exhibited increased SOC channel activity (Fig 2D, bottom panel . Splenocytes gated on CD4 were treated with anti-CD3-biotin, followed by cross-linking with streptavidin (S.A.) in the presence of exogenous calcium (top panel), or in the absence of exogenous calcium, followed by calcium re-addition to examine SOC channel function (bottom panel). Ionomycin (Iono.) stimulation was used at the end of each run to control for equivalent dye loading. Data is shown as the mean fluorescent ratio of Fluo-3 and Fura-Red. Representative data of three independent experiments are shown. expression levels are largely unaltered compared to control cells. In addition, FasL expression is augmented in Itpkb fl/fl CD4 + T cells at 2 hours, whereas the expression of Fas is unchanged (Fig 3A) . To further confirm these observations, control and Itpkb fl/fl CD4 + primary T cells were stimulated in vitro with PMA and Ionomycin, which bypass the Itpkb defect and allow cells to expand comparably in culture for 5 days, and then re-stimulated through the TCR to determine death effector gene expression levels. While Bim was slightly augmented, FasL expression was augmented 4-fold upon secondary stimulation of T cells from Itpkb fl/fl mice (Fig 3B) . These data clearly demonstrate the requirement for Itpkb in the negative regulation of gene expression for both death receptor-mediated and mitochondrial-mediated cell death pathways that are critical for proper T cell survival. 
The product of Itpkb, Ins(1,3,4,5)P4, inhibits open state Orai1 channels
In order to determine if the product of Itpkb, Ins(1,3,4,5)P4, specifically regulates the main components of the SOC channels in T cells, Orai1 and Stim1, we utilized HEK293 cells which stably express Stim1 and inducibly express Orai1 upon doxycycline treatment. This system has been described to increase SOC entry 20-fold in HEK cells [18] . With the HEK-Stim1-Orai1 cell line, we examined Orai1-mediated currents by whole cell patch clamp. As shown, the chelation of intracellular Ca 2+ with an EGTA/BAPTA solution stabilizes Orai1 into an open state (Fig 4A-4C ; step 2). Following the application of a cell membrane-permeable version of Ins (1,3,4,5)P4, 2,6-di-O-butyryl-myo-inositol 1,3,4,5-tetrakisphosphate-octakis (propionyloxymethyl) ester (Ins(1,3,4,5)P4-PM), 80% of the Orai1 currents are rapidly blocked. The further application of 2-APB, an ion channel blocker, exhibited little effect suggesting almost complete inhibition of the current was achieved by Ins(1,3,4,5)P4 or that Ins(1,3,4,5)P4-PM desensitized 2-APB sensitive channels (Fig 4A and 4D) . In contrast, Ins(1,4,5,6)P4, which is not made by Itpkb, as well as the DMSO vehicle did not inhibit Orai1 current (Fig 4B, 4C and 4D ). Despite the high concentrations of cell membrane-permeable Ins(1,3,4,5)P4 that were required to observe these effects, these concentrations are comparable to other studies [19] [20] [21] [22] . These data demonstrate that the product of Itpkb, Ins(1,3,4,5)P4, is a negative regulator of Orai1-mediated current.
Identification and characterization of Itpkb inhibitors
The data presented here demonstrate that Itpkb controls mature T lymphocyte function via the regulation of cytosolic Ca 2+ and the induction of genes involved in apoptosis. We reasoned that blockade of Itpkb with a LMW inhibitor should enhance AICD during the activation and/ or effector processes of autoreactive T cells, thus serving as an attractive strategy to eliminate these cells in the treatment of T cell-driven autoimmune disease. To identify a LMW inhibitor of Itpkb, we developed a biochemical assay using purified Itpkb protein to screen a 2 million compound library [14] . Following screening, co-crystallography with Itpkb, and medicinal chemical optimization, we identified GNF362 (Fig 5A) , a highly selective and potent orally available LMW inhibitor (IC50 of 9nM), which binds to the ATP-binding pocket of Itpkb (data not shown). GNF362 also potently inhibits Itpka, which is expressed in the brain, as well as Itpkc, which is more broadly expressed (Fig 5B) but has no activity against a panel of more than 150 protein or lipid kinases (S7 Fig) . Utilizing a Jurkat cell-based inositol production assay, we found that GNF362 specifically blocked Ins(1,3,4,5)P4 production but had no impact on Ins(1,4,5)P3 production (S8 Fig) . When applied to thymocytes, primary B or T lymphocytes, GNF362 augments SOC responses following antigen receptor cross-linking, with an EC50 of 12nM (Fig 5C and 5D ; S9A and S9B Fig) . The compound has no effect on SOC in Itpkb-deficient cells (S10A Fig) suggesting a high degree of selectivity, and enhances the SOC response of wild-type cells immediately upon addition to activated lymphocytes (S10B Fig) . In order to determine if Itpkb blockade in mature T cells can induce FasL-mediated T cell apoptosis, we examined the ability of T cells to proliferate in the presence of GNF362 as well as a blocking FasL antibody. GNF362 blocked T cell proliferation upon anti-CD3/28 stimulation, and the presence of a blocking anti-FasL antibody reversed this effect, suggesting that GNF362 enhanced FasL-mediated T cell death upon T cell activation (Fig 5E) . To understand if blockade of Itpkb disrupts T cell development in vivo, mice were dosed orally with GNF362 for 9 days and the percentage of CD4 + and CD8 + T cells was determined in the thymus and spleen.
Treatment with GNF362 lead to a dose dependent reduction in the percentage of CD4 + T cells in the thymus (Fig 5F) . Similar results were also observed in rats (data not shown). Pharmacokinetic data demonstrate that GNF362 reaches high systemic levels, exhibits moderate volume distribution, with good in vivo half-life, and is well tolerated with no adverse events in unmanipulated animals (see additional pharmacokinetic data in S11 Fig) . These data indicate that GNF362 selectively inhibits Itpkb, as it recapitulates the characteristics of Itpkb-deficiency. 
Itpkb inhibitors block T cell-driven autoimmune disease
Rat antigen-induced arthritis (rAIA) is a well-studied animal model of arthritis, due to its similarities with human Rheumatoid Arthritis (RA), and the involvement of T lymphocytes [23] . To determine the efficacy of GNF362 in rAIA, rats were immunized intra-dermally on Day -21 and -14 with methylated BSA (mBSA), followed by daily oral dosing of GNF362, or the steroid-based anti-inflammatory, dexamethasone, as a positive control. On Day 0, the rats received an intra-articular injection of mBSA into the knee joint. Knee joint swelling was measured on Days 2, 4, and 7, followed by histological analysis at the termination of the study. Serum antibody titers to mBSA were also measured on Days -21, -14, 0, and 7 (Fig 6A) . Upon repeated immunization with mBSA, antibody levels increase more than 2 million fold compared to unimmunized animals (S12 Fig). Treatment with GNF362 at 20mg/kg beginning on day -14, lead to a 265-fold reduction in antibody titers to mBSA compared to vehicle dosed immunized control animals, indicating that GNF362 can inhibit secondary and tertiary antibody responses (Fig 6B) . Furthermore, knee swelling was significantly reduced in both the 20mg/kg and 6mg/kg treatment groups of GNF362 by 47% and 34%, respectively (Fig 6C) . Upon histological examination and scoring of the knee joints, GNF362 at 20mg/kg significantly reduced inflammatory cell infiltrate, joint damage, and proteoglycan loss (Fig 6D, S13 Fig). Of note, the 6mg/kg dose of GNF362 shows minimal block in antibody production but shows significant inhibition of joint swelling. These data suggest that blockade of Itpkb by GNF362 could serve as a suitable therapy for rheumatoid arthritis by blocking T cell-mediated inflammation and auto-antibody responses.
Discussion
The studies described herein test the novel approach of blocking negative regulators of calcium signaling to augment SOC and induce AICD. Utilizing an inducible Itpkb knockout, the current study demonstrates a key role for the inositol kinase, Itpkb, and its product, Ins(1,3,4,5) P4, in blocking mature T lymphocyte death via the inhibition of components of the CRAC machinery, Orai1 and Stim1. To this end, we identified the selective LMW Itpkb inhibitor, GNF362, which not only recapitulated Itpkb-deficiency both in vitro and in vivo, but blocked disease in a rat model of arthritis. These data suggest that Itpkb may serve as a suitable target for T cell-mediated autoimmune disease.
Previously, we and others have demonstrated that the absence of Itpkb results in a complete block of thymocyte development at the double positive stage [10, 11] . In agreement with this finding, we show here that acute deletion of Itpkb in a conditional knockout system, leads to a rapid reduction in the number of single positive thymocytes, further supporting the notion that Itpkb plays a critical role in T cell development. Somewhat surprisingly, inducible deletion of Itpkb does not lead to reductions in peripheral lymphocyte numbers at least over the 1 month timeframe studied. While Itpkb appears dispensable for peripheral lymphocyte homeostasis it is required for T cell function. Immunization of mice following depletion of Itpkb revealed dramatic reductions in T-dependent antibody responses but normal responses to a Tindependent antigen. Stimulation of lymphocytes through antigen receptors in vitro demonstrate that Itpkb is necessary for the activation of mature T cells through the TCR, but is not required for mature B cells when activated through the BCR. These data indicate that while Itpkb is required for B cell development as reported previously, it may be dispensable for mature B cell function. In contrast, Itpkb is essential for both T cell development and mature T cell function. Interestingly, both mature T and B lymphocytes which have acutely lost Itpkb show enhanced SOC entry following antigen receptor stimulation. Patch-clamp electrophysiology reveals that Ins(1,3,4,5)P4 negatively regulates Orai1 and Stim1, the major components of the SOC machinery in T lymphocytes. Furthermore, TCR stimulation of Itpkb-deficient T cells results in greater induction of both death receptor-and non-death receptor-mediated cell death genes, such as FasL and Bim. Inhibition of FasL function partially restores the ability of Itpkb-deficient T cells to proliferate in response to TCR stimulation implicating FasL as a key mediator of Itpkb-controlled apoptosis.
The current study showing a central role for Itpkb in controlling T cell activation and apoptosis via regulation of Orai1/Stim but not T cell numbers contrast with a recent publication suggesting that Itpkb regulates peripheral T cell number and activation status. In this work, transient overexpression of Itpkb in the thymus of Itpkb -/-mice was used to partially overcome the block in T cell development and lead to the accumulation of low numbers of peripheral T cells that display an activated/memory phenotype [24] . The accumulation of activated memory CD4 cells could reflect homeostatic proliferation, an attempt to control underlying infection or secondary effects of transient high level Itpkb expression in the thymus. It will be interesting to determine the impact of pathogen challenge or long term deletion of inducible Itpkb fl/fl animals to resolve these discrepancies.
Numerous reports have described the phenotypes of both Orai1-and Stim1-deficient mice [25] [26] [27] [28] [29] . While both Orai1 -/-and Stim1 -/-thymocytes exhibit a complete abrogation of SOC entry, the development of αβ + T cells remains intact [25, 27, 30] . In contrast, while naïve T cells from both Orai1 -/-and Stim1 -/-mice also display impaired SOC entry, T cell function is significantly impacted as cells fail to induce cytokines upon TCR stimulation [25, 27, 30] . The comparison of Itpkb-deficient mice to both Orai1-and Stim1-deficient mice reveal an interesting inverse relationship which further validates that these genes act as negative and positive regulators, respectively, within the same signaling pathway. Firstly, while both Orai1-deficient and Stim1-deficient thymocytes and naïve T cells exhibit near complete blocks in SOC entry, Itpkb -/-cells display enhanced SOC entry. In the thymus, Itpkb-deficient mice exhibit a loss of single positive cells, whereas older Orai1-deficient mice (>12-16 weeks) accumulate these cells [26] . In peripheral T cells, Itpkb-deficient T cells exhibit enhanced FasL and Bim expression and FasL-mediated AICD as a result of elevated SOC entry, while Orai1-deficient T cells are resistant to AICD due to a lack of calcium-mediated induction of FasL and other mitochondrial-mediated death genes [26] . Together, these results are consistent with the hypothesis that the fate of developing and mature T cells is controlled by the magnitude of the TCR induced intracellular calcium influx through Orai1 and Stim1 and inhibited by Itpkb-induced production of Ins (1, 3, 4, 5) P4. Since T cell development occurs over a period of days, and T cell activation over a period of hours, these data suggest that the activation threshold required for positive selection versus T cell activation differ greatly and highlight the complexity of the requirement for calcium during various T cell development and activation processes. One question arising from the study presented here is how Ins(1,3,4,5)P4 regulates the inhibition of Orai1 channels. Ins (1, 3, 4, 5) P4 is thought to function as a soluble analog of phosphatidylinositol 3,4,5-trisphosphate (PIP3) by binding to and potentially competing for the pleckstrin homology (PH) domain of several signaling proteins [31] . Interestingly, it is believed that the redistribution of Stim1 is regulated by the binding of its C-terminal polybasic motif to the negatively charged phospholipids PIP2 and PIP3 in the plasma membrane [3, [32] [33] [34] . Furthermore, when the polybasic domain of Stim1 is removed in Orai1-expressing cells, enhanced activation of SOC channels is observed [35] , suggesting that this domain is required for the negative regulation of SOC channels. Numerous reports have also demonstrated how inhibitors of phosphoinositide synthesis, such as wortmannin, block SOC channel activity that is mediated by Stim1 [34, 36] .
Several members of the Tec family kinases are recruited to the plasma membrane by binding PIP3 via their PH domain, where they function to activate PLCγ-1, thus permitting the hydrolysis of PIP2 into diacylglycerol and Ins(1,4,5)P3, the substrate of Itpkb [37] . The Tec family members Itk, Btk, and Tec, have been shown to bind Ins(1,3,4,5)P4 via their PH domains [38, 39] . While the functional consequence of this interaction remains controversial, one could speculate that Ins (1, 3, 4, 5) P4 may function in a negative feedback loop to inhibit TCR proximal signaling events by promoting the dissociation of PH domain-containing proteins, such as Itk, from the plasma membrane. It is interesting to note that Itk-deficient mice exhibit reduced TCR-mediated calcium entry, resulting in impaired FasL-mediated AICD [40] . With respect to Ins(1,3,4,5)P4-mediated calcium inhibition, it is compelling to speculate that increased levels of Ins (1, 3, 4, 5) P4 may serve to bind to the C-terminal polybasic motif of Stim1 normally required for membrane association and ultimately dissociate the interaction between Orai1 and Stim1. Current efforts are focused on resolving this mechanism.
Blockade of T lymphocyte activation has been a dominant approach to developing novel treatments for autoimmune and inflammatory disorders. While drugs such as Neoral (cyclosporin) and Prograf (FK506) are efficacious they are not free of serious adverse events that limit their use and chronic immune suppression which renders patients susceptible to opportunistic infections [2] . A more desired outcome would be the selective blockade or depletion of pathogenic T lymphocytes while preserving normal T cell function. While several approaches are possible, the data presented here provide proof of concept for a new modality in which auto-reactive T cells are induced to undergo AICD via the elevation of cytoplasmic calcium. Importantly, since AICD requires TCR activation, such compounds may not impact peripheral lymphocyte homeostasis and may not require life-long treatment. Future studies testing the impact of Itpkb inhibition along with specific antigen stimulation may hold promise to achieve selective ablation of pathogenic T cells and provide new therapies to treat autoimmune disease.
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